Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 56
- Registration Number
- NCT03852446
- Locations
- 🇺🇸
Frontage Clinical Services, Inc., Secaucus, New Jersey, United States
Oral Bioavailability,and Food Effect Study and Single Ascending Dose PK Study in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2017-12-13
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT03372239
- Locations
- 🇨🇦
INC Research/inVentiv Health, Toronto, Ontario, Canada
A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 21
- Registration Number
- NCT03301636
- Locations
- 🇺🇸
Utah Cancer Specialists, Salt Lake City, Utah, United States
🇺🇸Mayo Clinic - Rochester, Rochester, Minnesota, United States
🇺🇸University of Iowa Hospital and Clinics, Iowa City, Iowa, United States
Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy
- Conditions
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 29
- Registration Number
- NCT03165188
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸NorthShore University HealthSystem, Evanston, Illinois, United States
NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors
- First Posted Date
- 2017-05-23
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 26
- Registration Number
- NCT03164603
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States
🇺🇸University of Florida, Gainesville, Florida, United States
A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-07-18
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 54
- Registration Number
- NCT02835729
- Locations
- 🇺🇸
Augusta University, Augusta, Georgia, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 41
- Registration Number
- NCT02648711
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸START Midwest/Cancer & Hematology Centers of Western Michigan, PC, Grand Rapids, Michigan, United States
🇺🇸South Texas Accelerated Research Therapeutics (START), LLC, San Antonio, Texas, United States
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
- First Posted Date
- 2015-07-20
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 81
- Registration Number
- NCT02502708
- Locations
- 🇺🇸
Children's Heathcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Augusta University, Augusta, Georgia, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer
- First Posted Date
- 2015-06-02
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 16
- Registration Number
- NCT02460367
- Locations
- 🇺🇸
Washington University in St. Louis, Saint Louis, Missouri, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-04-01
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 10
- Registration Number
- NCT02405585
- Locations
- 🇺🇸
University of Louisville, Louisville, Kentucky, United States
🇺🇸Lahey Clinic, Burlington, Massachusetts, United States
🇺🇸New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States